{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T22:13:59Z","timestamp":1703974439983},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.semnephrol.2012.12.009","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T14:46:54Z","timestamp":1359643614000},"page":"66-74","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of Arterial Hypertension in Obese Patients"],"prefix":"10.1016","volume":"33","author":[{"given":"Ulrich O.","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Benndorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2012.12.009_bib1","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ajh.2010.172","article-title":"Obesity-related hypertension: epidemiology, pathophysiology, and clinical management","volume":"23","author":"Kotchen","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/HJH.0b013e3283537347","article-title":"Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension","volume":"30","author":"Jordan","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/sj.ijo.0801854","article-title":"Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries","volume":"26","author":"Doll","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib4","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.amjhyper.2004.05.017","article-title":"Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled","volume":"17","author":"Bramlage","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib5","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00045415-200205000-00001","article-title":"Clinical management of the obese hypertensive patient","volume":"10","author":"Frohlich","year":"2002","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11906-005-0065-5","article-title":"Management of hypertension in overweight and obese patients: a practical guide for clinicians","volume":"7","author":"Dentali","year":"2005","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000095333","article-title":"Treatment of arterial hypertension in obese patients","volume":"151","author":"Wenzel","year":"2006","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11906-007-0090-7","article-title":"Management of arterial hypertension in obese patients","volume":"9","author":"Wenzel","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib10","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00001573-200207000-00006","article-title":"Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension","volume":"17","author":"Engeli","year":"2002","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1365-2796.2002.00982.x","article-title":"Who cares about the obese hypertensive patient?","volume":"251","author":"Sharma","year":"2002","journal-title":"J Intern Med"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib13","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0895-7061(99)00123-5","article-title":"The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study","volume":"12","author":"Jones","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11906-010-0123-5","article-title":"Drug mechanisms to help in managing resistant hypertension in obesity","volume":"12","author":"Jansen","year":"2010","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1161\/01.HYP.30.1.140","article-title":"Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial","volume":"30","author":"Reisin","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib16","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/00004872-200309000-00027","article-title":"Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study","volume":"21","author":"Grassi","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib17","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/01.hjh.0000188734.98463.82","article-title":"Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients","volume":"23","author":"Jordan","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib18","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/HYPERTENSIONAHA.106.084301","article-title":"Direct renin inhibition with aliskiren in obese patients with arterial hypertension","volume":"49","author":"Jordan","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib19","first-page":"69","article-title":"Hypertension","volume":"11","author":"Townsend","year":"2012","journal-title":"NephSAP by The American Society of Nephrology"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1467-789X.2011.00914.x","article-title":"Mechanisms linking obesity to hypertension","volume":"13","author":"Dorresteijn","year":"2012","journal-title":"Obes Rev"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib21","doi-asserted-by":"crossref","first-page":"17271","DOI":"10.1074\/jbc.R110.113175","article-title":"Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins","volume":"285","author":"Hall","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-2008-1065336","article-title":"New mechanisms to control aldosterone synthesis","volume":"40","author":"Willenberg","year":"2008","journal-title":"Horm Metab Res"},{"issue":"Suppl","key":"10.1016\/j.semnephrol.2012.12.009_bib23","doi-asserted-by":"crossref","first-page":"I56","DOI":"10.1161\/01.HYP.19.1_Suppl.I56","article-title":"Cardiovascular regulation in obesity-induced hypertension","volume":"19","author":"Rocchini","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/01.HYP.0000132568.71409.a2","article-title":"Is there a rationale for angiotensin blockade in the management of obesity hypertension?","volume":"44","author":"Sharma","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib25","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.2174\/1381612043382855","article-title":"Pathophysiology and treatment of obesity hypertension","volume":"10","author":"Wofford","year":"2004","journal-title":"Curr Pharm Des"},{"issue":"Suppl 1","key":"10.1016\/j.semnephrol.2012.12.009_bib26","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1210\/jc.2008-1363","article-title":"Obesity in children and adolescents","volume":"93","author":"Cali","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib27","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","article-title":"Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials","volume":"42","author":"Neter","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib28","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1161\/hy1201.101214","article-title":"History about the discovery of the renin-angiotensin system","volume":"38","author":"Basso","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000060163","article-title":"Angiotensin-converting enzyme inhibitors and progression of renal disease: evidence from clinical studies","volume":"135","author":"Wenzel","year":"2001","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib30","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1159\/000066656","article-title":"The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology","volume":"93","author":"Wolf","year":"2003","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib32","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2165\/00003495-200464220-00004","article-title":"Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system","volume":"64","author":"Scheen","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1559-4564.2007.06663.x","article-title":"Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial","volume":"2","author":"McFarlane","year":"2007","journal-title":"J Cardiometab Syndr"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00004872-200104000-00001","article-title":"Choice of drug treatment for obesity-related hypertension: where is the evidence?","volume":"19","author":"Sharma","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib35","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1161\/01.HYP.38.3.705","article-title":"Treatment of obesity hypertension and diabetes syndrome","volume":"38","author":"Zanella","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1161\/01.HYP.37.2.250","article-title":"Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis","volume":"37","author":"Sharma","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib37","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib38","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1523-1755.2005.00145.x","article-title":"Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications","volume":"67","author":"Wolf","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/eurjhf\/hfs033","article-title":"Aliskiren, ALTITUDE, and the implications for ATMOSPHERE","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2215\/CJN.01201005","article-title":"Direct renin inhibition with aliskiren in hypertension and target organ damage","volume":"1","author":"Muller","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/HJH.0b013e32834f6b43","article-title":"Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients","volume":"30","author":"Boschmann","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/MNH.0b013e328350261b","article-title":"AT2 receptor agonists: hypertension and beyond","volume":"21","author":"Steckelings","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib45","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2004.08.059","article-title":"Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes","volume":"95","author":"Kostis","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib47","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/HYPERTENSIONAHA.106.085654","article-title":"Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population","volume":"50","author":"Aksnes","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pcad.2006.02.002","article-title":"Use of aldosterone antagonists in resistant hypertension","volume":"48","author":"Calhoun","year":"2006","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","article-title":"Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension","volume":"46","author":"Saha","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib50","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/HJH.0b013e32834f8253","article-title":"A simple test to appreciate compliance with antihypertensive drug therapy","volume":"30","author":"Wenzel","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension","volume":"55","author":"de Souza","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib52","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/CIRCULATIONAHA.106.625400","article-title":"Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study","volume":"115","author":"Scholze","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib53","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension?","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib54","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/bmj.307.6903.537","article-title":"Obesity as a determinant for response to antihypertensive treatment","volume":"307","author":"Schmieder","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.jhh.1001137","article-title":"Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension","volume":"15","author":"White","year":"2001","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib56","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00271585","article-title":"Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension","volume":"31","author":"Pollare","year":"1988","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib58","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib59","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1161\/CIRCULATIONAHA.110.991869","article-title":"Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study","volume":"123","author":"Mahfoud","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib60","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1161\/HYPERTENSIONAHA.111.173799","article-title":"Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea","volume":"58","author":"Witkowski","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2012.12.009_bib61","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.lpm.2011.05.009","article-title":"[Renal-nerve ablation in patients with resistant hypertension: caution is still needed]","volume":"41","author":"Steichen","year":"2012","journal-title":"Presse Med"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929512002719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929512002719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T22:30:39Z","timestamp":1539901839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929512002719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0270929512002719"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2012.12.009","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}